Latest / Stock Movers / Abivax Up, Maersk Jumps, Sainsbury's Rise
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News, The.
- 0:08Speaker 2: Stock Movers Report, your roundup of companies making moves in
- 0:12Speaker 2: the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 1: Well, let's take a look at some stocks on the
- 0:17Speaker 1: move today in Europe. I'm Stephen Carroll and I'm joined
- 0:20Speaker 1: by Bloomberg reporter Chloe Melee. Chloe, good morning. Let's start
- 0:24Speaker 1: with Abbyvax, the biotech firm in France. Maneficting this morning
- 0:28Speaker 1: from some good news rit a drug trial.
- 0:30Speaker 3: Yeah, really really soaring this morning for ebbivex. So, as
- 0:34Speaker 3: you said, they came out with positive clinical trial results.
- 0:37Speaker 3: So this is a company that was in focus recently,
- 0:40Speaker 3: actually earlier this month, because it has this experimental inflammatory
- 0:45Speaker 3: bow disease drug which was really really super promising. But
- 0:49Speaker 3: then there were cases of cancer and that arose as
- 0:52Speaker 3: part of that trial, and you know, there was no
- 0:54Speaker 3: evidence that the cancers were actually related or linked to
- 0:57Speaker 3: the drug, but it led to shed plug regardless because
- 1:01Speaker 3: of those concerns that you know, those cancer cases would
- 1:04Speaker 3: then delay regulatory approval. But now today Abyvx came out
- 1:09Speaker 3: with the second part of that late stage clinical trial
- 1:12Speaker 3: and it really reassured investors and analysts and alysts have
- 1:16Speaker 3: said that this now really should put to rest any
- 1:19Speaker 3: concerns around potential malignancy, so the potential impact of those
- 1:23Speaker 3: cancer cases. They said that the events were noise rather
- 1:27Speaker 3: than a true safety signal, and that the results confirmed
- 1:30Speaker 3: how promising the drug could be. So this may actually
- 1:34Speaker 3: also revive some takeover rumors that were circulating pre trials.
- 1:38Speaker 3: So there were expectations that because of how promising that
- 1:40Speaker 3: drug could be, Abbyvex could be a really good m
- 1:43Speaker 3: and a target, and then obviously that retreated a little
- 1:46Speaker 3: bit when we had those cancer cases, but now that
- 1:49Speaker 3: we've got those positive clinical trial results, we could see
- 1:52Speaker 3: some of the takeover interests rise up again.
- 1:56Speaker 1: Yeah, really interesting story around abi vax. Thank you for
- 1:58Speaker 1: bringing us details of that. We're going to go next
- 2:00Speaker 1: to Mask, the shipping giant upgrading its profit outlook.
- 2:05Speaker 3: Yeah, a bit of an outlook boost for Mask. So
- 2:08Speaker 3: they'd said there was a very solid demand, especially in Asia,
- 2:12Speaker 3: and then also a global container market that looks to
- 2:15Speaker 3: stay very healthy throughout the rest of this year the
- 2:18Speaker 3: rest of twenty twenty six, and of course shipping companies
- 2:21Speaker 3: like Mask tend to do a quite well during period
- 2:24Speaker 3: of disruption. So we've been seeing always kind of container
- 2:27Speaker 3: rates rising when there's things like you know, geopolitical tensions
- 2:31Speaker 3: or tariff uncertainty, and of course over the last year
- 2:34Speaker 3: or so, there has been both because owners of cargoes
- 2:37Speaker 3: want to book early to kind of get ahead of
- 2:39Speaker 3: any potential disruption, so Musk has benefited from that. And
- 2:43Speaker 3: then freight volumes also do go up generally over the
- 2:46Speaker 3: summer because retailers try and get inventories back up for
- 2:51Speaker 3: the back to school and holiday shopping seasons, and so
- 2:54Speaker 3: all of those reasons they've all kind of aligned to
- 2:57Speaker 3: brighten that outlook for MASK and so we're the shes
- 3:00Speaker 3: up quite strongly this morning on the back of that
- 3:03Speaker 3: guidance boost.
- 3:04Speaker 1: Okay, so that's on Mersk, and then back in the UK,
- 3:08Speaker 1: Sainsbury's first quarter sales being described as better than feared.
- 3:12Speaker 3: Yeah, it's actually looking quite resilient. So if we look
- 3:16Speaker 3: at the sales growth for the fiscal first quarter, it
- 3:18Speaker 3: actually did come in slightly below expectations, and it is
- 3:22Speaker 3: worth noting that it is actually the slowest sales growth
- 3:25Speaker 3: in about four years for that quarter. But what real
- 3:29Speaker 3: short investors was actually the outlook. So it said that
- 3:32Speaker 3: profit would be about the same as last year, which
- 3:35Speaker 3: is a little bit more optimistic than what it said
- 3:37Speaker 3: in April when it worn that profit could actually drop
- 3:40Speaker 3: this year. So things seemed to be a little bit
- 3:43Speaker 3: better for Sainsbury's. It's a company that's been really banking
- 3:46Speaker 3: on value, so price matching with Ald for example, and
- 3:50Speaker 3: then having all of those promotions through its Nectar loyalty card,
- 3:54Speaker 3: and that's that's been a real focus for the more
- 3:58Speaker 3: and more established supermarket players like Tesco, Mins and Sainsbury's
- 4:02Speaker 3: because they want to retain market share against those discount
- 4:06Speaker 3: retailers like Aldi and Liddle, which have been taking a
- 4:10Speaker 3: lot more of their market share because consumers are received
- 4:13Speaker 3: quite price conscious, quite price sensitive these days. Sainsbury's did
- 4:17Speaker 3: flag continued uncertainty from the Iran War. Of course, there's
- 4:21Speaker 3: going to be the continued impact on the energy markets,
- 4:25Speaker 3: on supply chains, on consumer confidence. All of that is
- 4:27Speaker 3: still very relevant and it's unclear how much longer that's
- 4:31Speaker 3: going to be relevant for but that's going to be
- 4:33Speaker 3: something that creates a little bit of uncertainty around the
- 4:36Speaker 3: outlook going forward for Sainsbury's. But it had that kind
- 4:38Speaker 3: of cautious, cautiously optimistic tone that reassured investors in analysts.
- 4:44Speaker 2: This morning the Stock Movers Report from Bloomberg Radio. Check
- 4:49Speaker 2: back with us throughout the day for the latest roundup
- 4:51Speaker 2: of companies making news on Wall Street and for the
- 4:54Speaker 2: latest market moving headlines. Listen to Bloomberg Radio Live, catch
- 4:59Speaker 2: us on YouTube tube, Bloomberg dot com, and on Applecarplay
- 5:02Speaker 2: and Android Auto with the Bloomberg Business app.
- 5:09Speaker 3: Mm HM